Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia

Blood Adv. 2022 Jan 11;6(1):148-151. doi: 10.1182/bloodadvances.2021005998.

Authors

Yair Herishanu^{1

2}, Irit Avivi^{1

2}, Shai Levi², Gabi Shefer³, Yotam Bronstein^{1

2}, Miguel Morales Moshiashvili³, Tomer Ziv¹, Lydia Scarfò^{4

5}, Chava Perry^{1

2}, Paolo Ghia^{6

4

5}

Affiliations

¹ Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
² Department of Hematology, and.
³ Department of Endocrinology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
⁴ Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy; and.
⁵ Faculty of Medicine, Università Vita-Salute San Raffaele, Milan, Italy.
⁶ European Research Initiative on CLL (ERIC), Barcelona, Spain.

No abstract available

MeSH terms

Antibodies, Viral
BNT162 Vaccine
COVID-19 Vaccines
COVID-19*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
RNA, Messenger / genetics
SARS-CoV-2
Vaccination

Substances

Antibodies, Viral
COVID-19 Vaccines
RNA, Messenger
BNT162 Vaccine